| 000 | 01849cam a2200277 4500500 | ||
|---|---|---|---|
| 005 | 20250121162513.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aZelano, Johan _eauthor |
| 700 | 1 | 0 |
_a Holtkamp, Martin _eauthor |
| 700 | 1 | 0 |
_a Agarwal, Nivedita _eauthor |
| 700 | 1 | 0 |
_a Lattanzi, Simona _eauthor |
| 700 | 1 | 0 |
_a Trinka, Eugen _eauthor |
| 700 | 1 | 0 |
_a Brigo, Francesco _eauthor |
| 245 | 0 | 0 | _aHow to diagnose and treat post-stroke seizures and epilepsy |
| 260 | _c2020. | ||
| 500 | _a12 | ||
| 520 | _aStroke is one of the commonest causes of seizures and epilepsy, mainly among the elderly and adults. This seminar paper aims to provide an updated overview of post-stroke seizures and post-stroke epilepsy (PSE) and offers clinical guidance to anyone involved in the treatment of patients with seizures and stroke. The distinction between acute symptomatic seizures occurring within seven days from stroke (early seizures) and unprovoked seizures occurring afterwards (late seizures) is crucial regarding their different risks of recurrence. A single late post-stroke seizure carries a risk of recurrence as high as 71.5% (95% confidence interval: 59.7-81.9) at ten years and is diagnostic of PSE. Several clinical and stroke characteristics are associated with increased risk of post-stroke seizures and PSE. So far, there is no evidence supporting the administration of antiepileptic drugs as primary prevention, and evidence regarding their use in PSE is scarce. | ||
| 690 | _apost-stroke seizures | ||
| 690 | _aintracerebral haemorrhage | ||
| 690 | _atreatment | ||
| 690 | _apost-stroke epilepsy | ||
| 690 | _aischaemic stroke | ||
| 786 | 0 | _nEpileptic Disorders | Vol 22 | 3 | 2020-03-01 | p. 252-263 | 1294-9361 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/revue-epileptic-disorders-2020-3-page-252?lang=en&redirect-ssocas=7080 |
| 999 |
_c611340 _d611340 |
||